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Bonn, Bonn, GermanyAbstractAcute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between
0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical
symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and
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E-mail: j.e.arends@umcutrecht.nlIntroductionThroughout the world, acute hepatitis C virus (HCV) infections
remain common within speciﬁc populations. With approxi-
mately 170 million chronic carriers, there is a continuous pool
from which new infections arise [1]. Recent studies have re-
ported ongoing transmission within the major risk group ofClinical Microbiology and Infection © 2015 European Society of Cinjecting drug users (IDUs). Moreover, in recent years a new
epidemic of acute hepatitis C has emerged as a sexually trans-
mitted infection in human immunodeﬁciency virus (HIV)-
infected men who have sex with men (MSM) outside the
context of injecting drug use.
An acute HCV infection is mostly asymptomatic, or at least
stays undetected and leads to chronicity, in 74% (95% CI
72–79%) of reported cases [2]. Because of this silent infection,
patients are mostly diagnosed in the chronic phase. This results
in a paucity of studies evaluating viral and immunological
characteristics of acute HCV infection. Furthermore, because
of suboptimal study designs (often retrospective cohorts) and
small numbers of enrolled patients per study, many issues
remain unresolved. This review gives an overview of the cur-
rent knowledge and uncertainties, together with some futureClin Microbiol Infect 2015; 21: 797.e9–797.e17
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.03.026
797.e10 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIperspectives on acute hepatitis C epidemiology, virology,
immunology, and treatment.EpidemiologyThree major populations at risk for acute HCV infection can be
identiﬁed, each with differing modes of transmission, occurring
with different frequencies in different parts of the world: IDUs,
patients at risk of nosocomial infection, and HIV-positive MSM
[1].
Sharing of injecting equipment among drug users is a major
risk factor for acute HCV infection, and IDUs account for most
acute HCV infections worldwide. Currently, it is estimated that
there are 0.75–1.0 million active IDUs in Europe alone [3]. The
acute HCV infection incidence within this group varies between
2.7 and 66 per 100 person-years of follow-up (PYFU) [4]. This
results in an anti-HCV IgG prevalence of >50% in Europe and
approximately 67% worldwide [5,6]. A remarkable example of
the ongoing epidemic in IDUs outside Europe is provided by
young adult IDUs in the USA, with reported incidence rates as
high as 27 per 100 PYFU [7,8]. During the last decade, this
epidemic has expanded to rural areas, and has been associated
with increased prescription opiate use [9]. In the IDU popula-
tion, a variety of interventions have been implemented that
have resulted in a reduced incidence of acute HCV infection.
Most implemented interventions are opiate substitution and
needle exchange programmes, for which high coverage of
combined programmes is associated with a reduction in the
incidence of acute HCV infection [10,11]. However, the inci-
dence of HCV infection within IDUs does not seem to decline
to the very low levels that have been observed for HIV [12].
This difference might be atributable to the virological charac-
teristics of the virus, as HCV is approximately ten times more
likely to be transmitted through a needle puncture than HIV
[13]. Furthermore, HCV transmission might also occur through
sharing of drug use equipment other than needles, or via tat-
tooing (i.e. snorting straws).
Within theEuropeanhealthcare system,HCV transmission still
occurs. For example, according to the national surveillance sys-
tem in France, these infections (mainly invasive procedures)
account for up to 25% of all acute HCV infections diagnosed [14].
However, for hospitalized patients in Europe, the risk of acute
HCV infection via blood transfusion or via medicinal use of
contaminated needle injections has now been nearly abolished. In
contrast, high rates of acute HCV infections within healthcare
systems occur in developing countries. There are several devel-
oping countries that do not screen blood donors for HCV,
because of limited health budgets, leading to transmission ofHCV.
The most dramatic example is Egypt, in which the iatrogenicClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfecttransmissionofHCVduring the eraof parenteral antischistosomal
therapy mass treatment between 1960 and 1980 led to a
nationwide epidemic. As a result, 10–20% of the total Egyptian
population are currently infected, most of them with genotype 4.
Because of inadequate sterilization of healthcare equipment and
the high prevalence in the general population, HCV continues to
spread in Egypt [15]. Therefore, the annual number of new acute
HCV infections is estimated to be approximately 150 000 [16].
Intrafamilial transmission (3%) and heterosexual transmission
(0.07%) seem to be of limited importance [15,17].
In contrast to the low incidence of heterosexual HCV
transmission stated above, HCV is considered to be a sexually
transmitted disease among MSM. More speciﬁcally and for
partially unknown reasons, this acute hepatitis C epidemic has
been limited largely to HIV-positive MSM [18]. In Europe during
the past decade, the incidence rose from 0.08 per 100 PYFU up
to 1.75 per 100 PYFU [19–22] (Stellbrink et al., 17th Confer-
ence on Retroviruses and Opportunistic Infections, 2010,
Abstract 645). Currently, the epidemic appears to be levelling
off in The Netherlands [23]. Outside Europe (the USA and
Japan), this seems not to be the case, with recent reported
incidence rates being between 0.21 per 100 PYFU and 2.49 per
100 PFYU [24,25]. The acute HCV re-infection rate is even
higher, with reported rates of 7.8 and 15.2 per 100 PYFU
[26,27]. A supposed reason for this epidemic is the emergence
of national and international networks of HIV-positive men
preferably having unprotected sex with HIV-positive men (i.e.
serosorting) [28]. These could have arisen because of successful
HIV treatment, widespread internet use, and low-budget travel
possibilities [20,29]. Determinants for HCV transmission are
recreational drug use, sharing of snorting straws, receptive
ﬁsting, ulcerative sexually transmitted infections such as syphilis,
group sex, and rectal trauma with bleeding [22,30–32]. There
are also a number of potential mechanisms related to HIV that
might result in enhanced infectivity of and susceptibility to
HCV, including increased HCV loads in serum and semen, and
defects in the gastrointestinal immune system [33].
Despite adequate surveillance systems, there is still a signif-
icant fraction (up to 45%) of acute HCV infections for which the
mode of transmission cannot be identiﬁed. Suggested explana-
tions include denial of risk factors, and transmission by
acupuncture, tattooing, piercing or shaving by barbers [15,34].VirologyThere is currently heterogeneity in case deﬁnitions of acute
HCV infection. These differ widely between epidemiological,
immunological and intervention studies. Also, within these
subgroups, a wide range of criteria are used [35].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e9–797.e17
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method for detection of acute HCV infections [36]. This
approach, as is also true of demonstrating genoconversion by
genome ampliﬁcation assays, relies on the availability of a recent
prediagnostic sample. Although sample storage is common
practice within the HIV-co-infected patients in tertiary-care
centres in Europe, this is rarely done in other risk populations,
who do not regularly visit the outpatient clinics. Therefore, most
acute HCV infections will remain undiagnosed. Alternatively, the
combination of anti-HCV negativity and HCV RNA positivity at a
single time-point is also highly suggestive of an acute phase of
infection. However, in immunocompromised patients, sero-
conversion takes time, and it remains absent in 2–5% at 1 year
after infection [37,38]. If a patient is already anti-HCV positive
and HCV RNA-positive at the time of ﬁrst sampling, IgG avidity
testing can allow an estimation of infection duration [39]. For
diagnosis of re-infection, HCV genome ampliﬁcation is the
reference standard. However, HCV antigen, IgG avidity and IgG
titre measurements are promising alternatives [38,40].
Elevation of alanine transaminase (ALT) values is still used in
several deﬁnitions of acute HCV infection. However, cut-off
points differ widely across studies, from any value above the
upper limit of normal to 20 times the upper limit of normal
[35]. Interestingly, the presence of normal ALT values in the
acute phase of infection has been reported, in association with
ﬂuctuating viraemia [41]. Thus, excluding a diagnosis of acute
HCV infection in a high-risk individual by relying on a normal
ALT value may not be appropriate.
The process leading to either clearance or chronicity is
dependent on speciﬁc viral and host characteristics. These
determinants are heavily debated, because of the small numbers
of patients enrolled in different cohorts of patients with acute
HCV infection: IDUs, HIV co-infected, nosocomially infected,
or combined. In a recent multicentre study, patients with a
genotype 1 infection had an adjusted hazard ratio (AHR) of 1.56
in favour of clearance [42]. An additional important factor for
spontaneous clearance is the diversity in quasi-species:
increased quasi-species heterogeneity equates with a longer
estimated duration of infection and higher serum HCV RNA
levels. The heterogeneity in quasi-species can be partially
explained by the route of transmission (injecting drug use vs.
sexual) [43] and the imperfect function of the viral RNA po-
lymerase combined with a production of 1012 virions a day [44].
Important host-protective factors that have been associated
with spontaneous clearance are: non-black race (OR 5.15),
female gender (AHR 2.16) (with a protective effect of oes-
trogen), and host interferon (IFN) lambda gene 28B (IL28) C/C
genotype (AHR 2.26) [42,45,46]. Differences in host
interleukin-28 polymorphisms seem to constitute one of the
few genetic predictors of viral clearance, with C/C being theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infmost favourable genotype, followed by C/T and T/T [47]. The
closely linked rs12979860 and rs8099917 subtypes are associ-
ated with clearance, treatment effect and progression to
cirrhosis in patients with chronic HCV infection. For example,
within a study among 190 women, spontaneous clearance was
more common in patients with the C/C genotype (43/67; 64%)
than in those with the C/T genotype (22/90; 24%) or the T/T
genotype (2/33; 6%) (p < 0.001) [48]. The presence of hepatitis
B antigens seems to be protective for chronicity (OR 2.91) [49].
In contrast, HIV infection is associated with progression to
chronicity (OR 2.19) [45]. However, when the immune status
of a patient can be restored by combined antiretroviral therapy,
the chance of spontaneous clearance seems to increase [50].
Several models have been developed to prevent unnecessary
pegylated IFN (pegIFN)-based treatment for patients who
would have cleared HCV spontaneously [42,51–54]. These
prediction algorithms rely on pathophysiological causative
mechanisms, but also on clinical or biochemical ﬁndings, such as
jaundice, bilirubin elevation, or the IP-10 level, which may be a
reﬂection of a well-functioning immune system. These algo-
rithms reliably predict spontaneous cure rates, but have not
been prospectively validated.ImmunologyCellular response
Mounting an effective T-cell response is a key immunological
element of spontaneous viral clearance [55]. Speciﬁcally for
acute HCV mono-infections, several studies have demonstrated
that a broad and vigorous HCV-speciﬁc CD4+ and CD8+ T-cell
response is associated with clearance of the infection [56–59].
Similar observations linking T-cell responses to spontaneous
viral clearance have been made in HIV-infected patients with an
acute HCV infection. However, comparisons between patients
with acute HCV mono-infection and HIV/acute HCV co-
infection have revealed impaired responses in the latter
group, which may account for the reduced clearance rates
observed in this patient group [59,60].
The innate immune response also plays a role in the acute
stage of the disease, although its exact contribution is unclear.
HCV RNA is sensed through either the helicase RIG-I, which
forms a complex, or Toll-like receptors, ultimately leading to
the production of IFN-α and upregulation of IFN-stimulating
genes [61,62]. Differences in the production of IFN-α, both in
plasma and in the liver, have been attributed to the observed
differences in spontaneous viral clearance rates between pa-
tients with acute HCV mono-infection and those with HIV/
acute HCV co-infection [63,64]. Several HCV proteins have
been shown to interact with this intracellular signalling cascade,ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e9–797.e17
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signalling protein downstream of RIG-1 [62,65].
Humoral response
The role that antibodies play in the spontaneous clearance of
acute HCV infection is less well understood [66]. Early in vitro
studies showed that highly speciﬁc neutralizing antibodies
(NAs) against the HCV envelope proteins E1 and E2 were
frequently present, with hypervariable region 1 in E2 being an
important target for NAs. However, technical limitations were
encountered, e.g. the use of pseudoparticle cell systems
enabling only a limited number of viral genotypes, together with
the use of the general reference strain H77c. Despite the
development of the JFH-1 cell culture system, which acceler-
ated NA research, how HCV evades neutralization still requires
further deﬁnition. This can be partly explained by cell-to-cell
spread via tight junctions [67], and partly by the high speci-
ﬁcity of these antibodies for variants that can subsequently
mutate under selection pressure. Despite evasion of the im-
mune system, there is clinical evidence for a signiﬁcant role of
NAs in protection against HCV. For example, from early hep-
atitis B immunoglobulin vaccination studies in liver transplant
patients, it became apparent that lower HCV recurrence rates
were seen in those patients receiving hepatitis B immunoglob-
ulin [68]. Furthermore, in patients with acute HCV infection
patients, high NA titres corresponded with spontaneous viral
clearance [69]. Similarly to the pattern of T-cell responses,
broadly neutralizing antibodies are associated with resolving
infections [69]. Such NAs may recognize conformational epi-
topes most often around the binding site for CD81, one of the
co-receptors for HCV cell entry [70]. Additionally, although it
is a rare occurrence, NA binding to linear epitopes has been
described [71], leading to the discovery of monoclonal anti-
bodies such as AP33, with potent neutralization capacity [72].Vaccination
One question in the era of direct-acting antivirals (DAAs) is
whether we still need a vaccine. It could be reasonably argued
that, because most people are unaware of their infection and
the limited symptoms of disease, vaccination is the most
effective way of eradicating HCV. Moreover, adequate treat-
ment gives no protection against re-infection [27]. However,
the correlates of immunity for HCV are still largely unknown,
hampering vaccine development [73]. On the basis of the
chimpanzee HCV model, a limited number of vaccine candi-
dates have advanced into human clinical testing, with varying
degrees of success [74]. Different approaches have been tried:
vaccines based on recombinant proteins or peptides, DNA, and
viral vectors. Combining two of these, e.g. a viral vector with a
protein, seems attractive, potentially providing both humoralClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectand cellular immunity [75]. For example, the combination of an
adenoviral vector with a recombinant HCV E1E2 protein was
demonstrated to elicit a strong antibody and T-cell response in
mice and guinea pigs [76]. A recent phase 1 human study
showed that very high levels of CD4+ and CD8+ T-cells can be
induced with viral vectors based on rare adenovirus serotypes:
currently, a phase 2 study using such vectors is underway to
investigate the efﬁcacy of such a prime-boost T-cell vaccine
approach in an injecting drug-using community in Baltimore
[77].TreatmentOptimal timing of treatment for acute HCV infection
In clinical practice, the optimal timing of onset of treatment
remains controversial. It is not easy to predict when the
chances of spontaneous clearance outweigh the effects of
pegIFN-based treatment. A model has been made to predict the
efﬁcacy of treatment in comparison with the chance of spon-
taneous clearance, and proposes treatment within the ﬁrst 2
months or 4 months after transmission [52]. However, this
model assumes a reliable transmission date, which is often not
available. As a result, most physicians refrain from applying
treatment during at least the ﬁrst month after diagnosis, to
await spontaneous clearance. This is in line with the current
European AIDS treatment network (NEAT) and European Aids
Clinical Society guidelines, recommending a 4-week period to
observe a potential HCV RNA decline of at least 2-log, after
which the chance of spontaneous clearance becomes substan-
tially higher [36] (Vogel et al., 17th Conference on Retroviruses
and Opportunistic Infections, 2010, Abstract 640). Without this
2-log decline, treatment can be initiated. However, observa-
tions from a large international study on 632 participants with
acute HCV mono-infection do not support this approach.
Among patients with spontaneous clearance, 33% became HCV
RNA-negative later than 6 months after the estimated date of
infection [42]. This supports the policy of waiting for a longer
period. As a result, current European Association for the Study
of the Liver and American Association for the Study of Liver
Diseases (AASLD) guidelines are inconclusive about the
observation period [36] (AASLD/IDSA/IAS–USA: http://www.
hcvguidelines.org). This is also supported by a study in 130
mono-infected patients who were treated after a 12-week
delay, and showed similar sustained viral response (SVR) rates
as those in studies using a 4-week observation period [78]. In
contrast, data from the German HepNET III study on acute
HCV mono-infection did not support a 12-week delay in
treatment after diagnosis, as this was associated with a lower
SVR rate than immediate treatment (SVR, 54% vs. 67%) [79].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e9–797.e17
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driven by the fact that more patients in the delayed treatment
group were lost to follow-up, the authors concluded that
delayed treatment can be as effective when protocol and
treatment adherence can be ensured. Finally, in the light of
pegIFN-free therapies with cure rates of >90% in patients with
chronic HCV infection, the debate will continue, and delay of
treatment will be expanded to wait for the last patient to clear.
Rationale for treatment
Patients with acute HCV infection have historically been treated
with shorter-duration regimens, yielding higher SVR rates, than
those used in patients with chronic infection. With new DAAs
being licensed, the treatment of chronic HCV infection has
become very safe and effective, and early treatment may have no
advantage with respect to SVR rates. As a result, current AASLD
guidelines advocate waiting until infection becomes chronic and
selecting treatment regimens without pegIFN (AASLD/IDSA/
IAS–USA: http://www.hcvguidelines.org). However, there are
still a number of reasons to treat in the acute phase, e.g. to
reduce viral transmission or to treat symptomatic patients. In
many countries, the most important reason for treating with
pegIFN-based regimens during acute infection is the lack of in-
surance coverage of new DAAs in patients without an urgent
medical need for HCV therapy. This is certainly not restricted to
resource-limited settings. In several European countries (e.g.
Belgium, The Netherlands, Spain, Italy, and the UK), DAAs can
only be used in patients with advanced ﬁbrosis or cirrhosis. Even
when DAAs can be used regardless of ﬁbrosis grade, DAAs are
not European Medicines Agency-registered or Food and Drug
Administration-registered for the treatment of acute HCV
infection, as their efﬁcacy and safety in patients with acute HCV
infection have not yet been studied. Therefore, despite the
known side effects, pegIFN-based treatment for acute HCV
infection will remain the only available option in many countries
for several years to come.
Treatment regimen for acute HCV infection
Currently, pegIFN-α as monotherapy, or in combination with
ribavirin (in patients with HIV co-infection), is still the only
treatment that has been adequately studied in patients with
acute HCV infection and is approved for this indication. In
patients with acute HCV mono-infection, cure rates between
71% and 94% have been reported with pegIFN-α monotherapy
[80,81]. As the therapeutic mechanisms for pegIFN-α and
standard IFN-α are similar, starting the treatment with high-
dose standard IFN-α 2a or 2b is common in resource-limited
settings in which pegIFN-α is not available or more costly.
The wide variety of cure rates within the HIV-co-infected
population makes it difﬁcult to interpret the effects ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infdifferent treatments. Small, mostly underpowered, cohort
studies with a variable genotype distribution have shown an
average cure rate of 61% (standard deviation of 17) [82].
Although its role remains controversial, ribavirin is often added
to pegIFN-α for the treatment of patients with HIV co-
infection, resulting in higher SVR rates in general. Most physi-
cians start with pegIFN-α and ribavirin, with tapering or
discontinuation of ribavirin if adverse events occur [36,82].
However mono-therapy could be suitable in a subset of co-
infected patients treated within the ﬁrst weeks after diagnosis
of acute HCV infection [83].
Duration of treatment
In most clinical studies and treatment guidelines, the duration of
pegIFN-α treatment in HCV-mono-infected patients has been
24 weeks. However, 12 weeks of treatment has also been used
successfully in observational studies, with cure rates of 72% and
74% [84,85]. In a recent large, randomized controlled trial, no
difference in response rates between 24 weeks of pegIFN-α and
12 weeks of pegIFN-α (with or without ribavirin) was observed
[78]. As this study concluded that the only predictor of SVR
was a rapid viral response at week 4, it is remarkable that this
decision rule is not integrated in current European Association
for the Study of the Liver guidance [36].
For HIV-co-infected patients, the NEAT acute HCV infection
guideline suggests that treatment duration should be based on
the week 4 HCV RNA load. If HCV RNA is <600 IU/mL, a
treatment duration of 24 weeks is recommended; if it is
>600 IU/mL, a treatment duration of 48 weeks is recom-
mended [82,86].
DAAs in the treatment of acute HCV infection
Several new classes of DAAs have shown cure rates of >90% in
patients with chronic HCV infection, for both HIV-negative and
HIV-positive patients. For the treatment of acute HCV infec-
tion, only telaprevir, a ﬁrst-generation HCV protease inhibitor,
has been tested in a pilot study of acute HCV infection, in 19
co-infected patients. It was given for only 12 weeks in combi-
nation with pegIFN-α and ribavirin, and a promising 84% SVR
rate was seen [87]. If these results can be conﬁrmed by other
ongoing studies, the use of ﬁrst-generation protease inhibitors
for the treatment of acute HCV infection could become an
effective treatment strategy (Boesecke, International HIV/Viral
Hepatitis Co-infection Satellite Meeting, 2014: https://www.
eiseverywhere.com/ﬁle_uploads/69a8663ad9057a7644861df13
9914b08_ChrisBoesecke.pdf; Hullegie et al., Conference on
Retroviruses and Opportunistic Infections, 2015, Abstract 669).
Currently, studies on IFN-free DAA-containing regimens are
being set up (Table 1) [88]. However, so far, no DAA-
containing regimen has been extensively studied in patientsectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 797.e9–797.e17
TABLE 1. Current and future studies with direct-acting antivirals in patients with acute hepatitis C virus (HCV) infection
Study name Coordinator Therapy HCV genotype Duration (weeks) HIV status Number of patients
DAHHS EMC BOC + pegIFN + RBV 1 12 + 60
CHAT UKB TPV + pegIFN + RBV 1 12 + 40
DARE-C 1 Kirby Institute, Australia TPV + pegIFN + RBV 1 8–24 – /+ 20
DARE-C2 Kirby Institute, Australia SOF + RBV All 6 – /+ 20
SWIFT-C ACTG SOF + RBV All 8 vs. 12 + 44
SOL UKB SOF + LDV 1,4 6 + 20a
Hep-Net Acute HCV MHH SOF + LDV 1 6 — 20a
ACTG, Aids Clinical Trials Group, USA; BOC, boceprevir; EMC, Erasmus Medical Centre, The Netherlands; HIV, human immunodeﬁciency virus; LDV, ledipasvir; MHH,
Medizinische Hochschule Hannover, Germany; pegIFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir; TPV, telaprevir; UKB, Universitätsklinikum Bonn, Germany.
aEstimated number.
797.e14 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIwith acute HCV infection. Therefore, pegIFN-based therapy is
likely to remain part of the treatment armentarium for acute
HCV infection for the next several years. DAAs will be added
consecutively, with decreasing treatment duration as a result
(Fig. 1).Conclusions and future directionsThe ﬁeld of acute HCV infection remains complex, because of
limited research into prevention, adequate diagnosis, treatment
initiation, and treatment regimens. Despite all efforts, there is
still no conclusive evidence for a decline in the spread of the
virus within major risk populations. Even with high incidence
rates, the identiﬁcation and inclusion of substantial numbers ofFIG. 1. Possible future treatment for acute hepatitis C virus infection
treatment and response prognosis. pegIFN, pegylated interferon; SVR,
sustained viral response.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectindividuals with acute HCV infection to allow trials to have
sufﬁcient power remains very challenging.
The availability of new DAAs will probably result in more
cured patients. The high rates of adverse events and discon-
tinuations with pegIFN-based therapy have led to delays in
treatment initiation in acute infections, with possible resultant
onward transmission of infection. Because of the projected
signiﬁcant costs and, therefore, limited worldwide availability of
DAAs, it remains to be seen whether more advanced treatment
approaches will have a substantial effect. The availability of a
potent anti-HCV vaccine would be helpful, although the results
from trials of candidates are still eagerly awaited.
Therefore, increased attention should be focused on the
screening and detection of acute HCV infection cases. How-
ever, reducing the size of the infected population will probably
not lead to the total extinction of HCV infections, as acutely
infected individuals might drive onward HCV transmission [89].
The best way to eradicate a virus remains early identiﬁcation,
for which better diagnostic tools are necessary, in combination
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